Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis
Milo Gatti, Riccardo De Paola, Beatrice Giorgi, Federico Pea · 2026
Read Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis by Milo Gatti, Riccardo De Paola, Beatrice Giorgi, Federico Pea (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13537137.txt.
Description
Milo Gatti, Riccardo De Paola, Beatrice Giorgi, and Federico Pea pooled head-to-head studies in 2026 of two drugs for a hard-to-treat germ. The germ, Pseudomonas aeruginosa, can shrug off many drugs in grave lung and blood infections. Both study drugs pair a classic killer with a shield-breaker and are first-line picks. Past field reports clashed on which heals more and which breeds new resistance.
Six field studies with more than a thousand patients were pooled. The first drug healed a clear share more patients than the second. Rates of germ kill failure, new resistance at ninety days, and death at thirty days were much the same. Bias checks were run on all studies. The authors read the heal edge as real but modest.
Catalog record
| CREATOR | Milo Gatti, Riccardo De Paola, Beatrice Giorgi, Federico Pea |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |